Patent ID: 7833795

Claim:
A method of assessing cardiovascular risk in a subject contemplating therapy with a COX-2 selective inhibitor compound the method comprising: measuring the level of an isoprostane in a body fluid of the subject prior to administration of the compound, measuring the level of the isoprostane in the body fluid of the subject at about four hours after administration of the compound, and determining a ratio by dividing the level of the isoprostane in the body fluid of the subject at about four hours after administration of the compound by the level of the isoprostane in the body fluid of the subject prior to administration of the compound, comparing the determined ratio to a database of ratios for a representative population, wherein the database is divided into quartiles, wherein the subject has not taken a non-steroidal anti-inflammatory drug or a COX-2 selective inhibitor compound for at least two weeks prior to administration of the compound, and wherein a ratio of the level of the isoprostane about four hours after compound administration to the level of the isoprostane prior to compound administration in the upper quartile is indicative of increased cardiovascular risk in the subject.